Adjuvant treatment for uterine leiomyosarcoma.
The aims of this study were to evaluate outcomes in women diagnosed with uterine leiomyosarcoma (LMS). A retrospective chart review was conducted. Fifty-eight women with LMS were identified. Of the evaluable 52 patients (six patients were excluded), 73% had Stage I/II disease, and 27% had Stage III/IV disease. Sixty-three percent of patients received chemotherapy (97% doxorubicin-based therapy), eight percent received radiation alone, and 29% received no therapy. For patients with Stage I/II disease, no improvement in OS was demonstrated when adjuvant therapy was administered. There was a significant difference in OS (p = 0.0005) for patients with advanced Stage (III/IV) disease that received adjuvant chemotherapy. OS of the entire group, when adjusted for stage, failed to reveal a significant survival advantage for those receiving chemotherapy-based (p = 0.22). The present findings suggest further research into the role of chemotherapy in early stage disease is needed to better refine optimal treatment.
Division of Gynecologic Oncology, Roswell Park Cancer Institute, Elm Street, Buffalo, NY, USA. stacey.akers@roswellpark.org
S N
SN
Akers
Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA.
A
A
Groman
Division of Gynecologic Oncology, Roswell Park Cancer Institute, Elm Street, Buffalo, NY, USA.
K
K
Odunsi
Division of Gynecologic Oncology, Roswell Park Cancer Institute, Elm Street, Buffalo, NY, USA.
S
S
Lele
Division of Gynecologic Oncology, Roswell Park Cancer Institute, Elm Street, Buffalo, NY, USA.
P J
PJ
Frederick
D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*